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This article introduces a series of articles addressing the safety
of esteriﬁed propoxylated glycerols (EPG or EPGs hereafter), a fam-
ily of fat- and oil-like substances that resemble triglycerides in
structure and appearance, but have been modiﬁed to prevent or
limit their digestion when consumed in food.
EPGs have been studied extensively, but the majority of this
information is not publicly available. As such, the present series
provides an overview of EPGs, especially their safety. This intro-
duction provides a general summary of the history, composition,
metabolism, and safety of EPGs. The six articles that follow [muta-
tion assays; 90-day study in rats; 90-day study in micropigs;
one-generation study in rats; teratology study in rabbits; human
8-week study] discuss in more detail a subset of representative
studies for assessment of the safety of EPGs when used as fat
substitutes in foods.2. History
EPGs were invented in the 1980s by ARCO Chemical Company
and investigated as a ﬂexible technology for replacement of triglyc-
eride fats in food products. ARCO entered into a joint agreement
with Bestfoods (CPC, International) to develop EPG application in
selected food products, and a comprehensive GLP- and GCP-
compliant safety testing program was developed with FDA guid-
ance. This research program was completed in the mid-1990s.However, Bestfoods withdrew from the joint venture shortly there-
after, and ARCO was unable to continue the project. Activity on the
project resumed a number of years ago when the technology was
assigned to a non-proﬁt organization afﬁliated with Kansas State
University. A new partner, Choco Finesse, LLC, has now been
granted development rights and is in the process of commercializ-
ing EPGs for selected food ingredient applications.
When EPGs were ﬁrst developed, it was expected that premar-
ket approval via a food additive petition (FAP) to the U.S. FDA
would be required to enable food uses. However, there is now a
considerable data base of information on the safety and tolerability
of fat substitutes, based on pre- and post-marketing experience
with various products, including P&G’s Olestra (Olean™) (see
Table 1). It might therefore be possible to establish, based on scien-
tiﬁc procedures including a discussion of expected adverse effects
based on a history with similar substances, that the use of EPGs in
certain foods is GRAS (generally recognized as safe). If the safety of
EPGs is generally recognized by qualiﬁed experts, it would exempt
EPGs from the deﬁnition of a food additive, and therefore from
premarket approval requirements. A determination that the use
of EPGs is GRAS requires the same quantity and quality of scientiﬁc
evidence as is required for a FAP, but this evidence must be gener-
ally known and accepted (62 FR, 18939; April 17, 1997). The pres-
ent series of articles provides evidence consistent with this
common knowledge element of the GRAS standard.3. Composition
Esteriﬁed propoxylated glycerols (EPGs) are produced by a
three-step process: ﬁrst, fats and oils are split into glycerol and
fatty acids. Then, glycerol is reacted with propylene oxide to
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Fig. 1. Basic structure of triglycerides vs. EPG.
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Fig. 2. EPG nomenclature. The following is the designated identiﬁcation of the
‘‘core’’ version representative of the current commercial variants.
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hydroxyl groups. Finally, the propylene glycol-substituted glycerol
is reacted with fatty acids resulting in their esteriﬁcation with the
hydroxyl moieties of the PGUs to produce EPG. Importantly, the a-
methyl group of the PGU sterically blocks access of lipase to the
ester linkage thus impairing normal lipid digestion of EPGs. EPG
oligomers in which not all glycerol hydroxyls are attached to at
least one PGU are susceptible to lipase action and partial digestion.
Fig. 1 provides a schematic representation of the composition of
EPGs compared to conventional triglycerides.
The ‘‘crude’’ EPG produced after esteriﬁcation is then reﬁned,
ﬁltered, hydrogenated (if necessary) using standard edible oil
reﬁning methods, and fortiﬁed with a tocopherol mixture to
improve the stability of the product. This stabilizer is a mixture
of a-, c-, and d-tocopherols added to prevent oxidation and to
ensure a long shelf-life of this fat substitute without the develop-
ment of undesirable off-odors and off-tastes with time.
A large variety of EPG versions can be manufactured using com-
mercially available sources of fatty acids split from vegetable-
sourced fats and oils. These versions can be made to resemble
and function like vegetable oils, semisolids like butter, or solids like
lard, depending on the source of the fatty acids used and the num-
ber of PGUs inserted onto the glycerol backbone. Each form of EPG
has a particular designation (Fig. 2), where EPG is followed by a
number that represents the average total PGUs per glycerol, the
source of the fatty acids, and for versions that use more than one
source of fatty acids, the ratio. The letter ‘‘H’’ is used to indicate
it is a hydrogenated EPG version.
A core version was selected as the likely representative form for
initial commercial development. Selection was made based on the
preference for: (1) a version that was solid at body temperature to
minimize undesirable gastrointestinal effects; (2) high content of
saturated fatty acids to reduce potential caloric availability; and
(3) a mean degree of propoxylation (PO-5) that would assure all
glycerol hydroxyls were blocked by at least one PGU unit to pre-
vent susceptibility to lipase digestion. In addition to the core EPG
version, several other EPG variations were selectively investigated.
These versions differed in the number of PGUs (up to 14) and fatty
acid source, which also resulted in liquid versions. This ‘‘matrix’’ of
test substances conﬁrmed predictable characteristics with respect
to digestibility and calories, as well as gastrointestinal tolerance.
Use of a matrix approach to establish the safe use of a family of
related compounds is not unusual. Table 2 lists some examples
of substances approved for human food use based on a matrix
approach.
EPG formulations are actually mixtures consisting of multiple
oligomers, and the designations of EPG-05, EPG-08, EPG-14, etc.
refer to the number of PGUs of the predominant oligomer in the
mixture; 5, 8, and 14, respectively, in each of these. The graph in
Fig. 3 shows the oligomer distribution in EPG-05, a form of EPGTable 1
Summary of EPG and other fat substitutes.
Name Company Regulatory status Caloric
content
Form
Caprenin P&G GRAS (1992) 5 Solid
Salatrim Nabisco/
Cultor
GRAS (1995) 5 Solid &
liquid
Olestra
(Olean™)
P&G FAP (1996) GRAS (2008,
2010)
0 Solid
EPGs Chocoﬁnesse GRAS evaluation in
progress
0.7 Solid
Sorbestrin Cultor/
Danisco
Not ﬁled 1.5 Liquid
GRAS, generally recognized as safe; FAP, food additive petition.that has been extensively studied; Table 3 provides a representa-
tive fatty acid composition. The oligomer distribution is reproduc-
ible and tightly controlled by thermodynamic factors (Cooper and
Polley, 1995).
4. Safety
Table 4 provides an overview of the studies related to the safety
of EPG. Experimental animal studies showed that EPG was not
associated with acute (single-dose), subchronic (90-day), or
chronic (1-year) oral toxicity; genotoxicity; carcinogenicity (2-
year); skin or eye irritation; dermal sensitization; or adverse
effects on reproduction and offspring development. Animals in
these studies were exposed to diets containing a constant level
of 5% EPG (w/w) or adjusted to deliver up to 5 g/kg of body
weight/day.
Ingested EPG is not metabolized or absorbed to any signiﬁcant
degree. The results of rat studies with radiolabeled EPG-08 oleate
and EPG-14 oleate (14C radiolabel on either the PGU or the fattyFood product applications
Candy bars
Chocolate chips, granola bars, cookies
Savory snacks, unpopped popcorn, prepackaged cookies; many food uses,
including frostings/icings
Chocolate-based products and ingredients
Dressings, peanut butter, cooking oil
Table 2
Food substances cleared by FDA using the matrix testing approach.
EXAMPLES:
 Modiﬁed Starches:
Hydroxypropyl distarch glycerol (up to 10% PO)
Hydroxypropyl distarch (up to 25% PO)
 Block polymers of EO and/or PO
 Polyglycerol fatty acid esters
 Rosins
Fig. 3. Oligomer distribution of glycerol polyether polyols in EPG-05.
Table 3
Representative fatty acid composition of H-EPG-05 HR/SO 9:1.
Fatty acid % (as oleic)
Palmitic, C16:0 1.5–12
Stearic, C18:0 47–70
Arachidic, C20:0 6–20
Behenic, C22:0 14–30
Arachidic + behenic 25–40
Oleic, C18:1 0–10
Linoleic, C18:2 0–6
Linolenic, C18:3 0–1
Total trans fat <0.25*
* Once incorporated into the food product, trans fat levels would be diluted to
trace amounts likely to be undetectable by present analytical methods.
Table 4
Overview of EPG safety studies.
Study type Species
Tolerance Dog, rat
Pharmacokinetics (ADME) Rat
Genetic toxicity (mutagenicity and
chromosome aberrations in vitro and
in vivo)*
Bacterial and mammalian
systems
Acute toxicity (oral; dermal & eye irritation) Rat, rabbit
Dermal sensitization Guinea pig
Subchronic toxicity (oral)* Rat, mouse, dog, micropig
Chronic (1-year) toxicity Rat, mouse, dog, micropig
Carcinogenicity (2-year) Rat, mouse
Reproductive toxicity (1-generation, 3-
generation)*
Rat
Developmental toxicity (teratology)* Rabbit
Tolerance and effects on fat-soluble vitamins
and other nutrients*
Human
* For more details, see other articles in this series.
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70–80% of an oral dose was recovered in the feces, 10–20% in the
urine, and the remaining fraction was recovered in the expired
air, presumably as carbon dioxide; no accumulation in tissues
has been observed. A greater number of PGUs inserted on the glyc-
erol backbone was associated with greater resistance to degrada-
tion. Both forms of EPG investigated were liquid and contained a
signiﬁcant percentage of unsaturated fatty acids – factors that
would tend to increase susceptibility to digestion by intestinal
microﬂora. The core version for commercial applications is solid
at body temperature and contains almost exclusively saturated
fatty acids – factors increasing resistance to microﬂoral digestion
and impairing caloric release (see Table 2).
As a substance that passes through the gastrointestinal tract
largely unchanged, ingested EPG was not expected to result in
systemic toxicity, which the safety data demonstrate. However,
additional consideration was given to undesirable effects resulting
from its presence in the intestine; speciﬁcally, possible interfer-
ence with the absorption of nutrients (e.g., lipid-soluble vitamins)
and passive oil leakage in stool, two effects previously associated
with olestra consumption.
4.1. EPG and nutrient absorption
EPG is intended to replace fats and oils in food products, and
some similar substances have been shown to interfere with the
absorption of lipid-soluble nutrients from the gastrointestinal
tract. For example, pigs fed olestra for 4–26 weeks had lower liver
and serum concentrations of vitamins A and E, and lower serum
25-OH vitamin D, in a dose-dependent manner (reviewed by
Tulley et al., 2005). Olestra has also been associated with poten-
tially clinically signiﬁcant lower absorption of fat-soluble vitamins
in humans (Schlagheck et al., 1997).
Experimental animal studies of EPG have shown some treat-
ment-related effects on the levels of some fat-soluble vitamins.
Speciﬁcally, dietary intake of EPG was associated with lower levels
of liver vitamins A (retinol) and E (tocopherol), and serum vitamin
D across multiple animal species, in both sexes, and generally in a
concentration-dependent manner. Despite these observations,
which were statistically signiﬁcant in many cases, none of the ani-
mals in any of the studies exhibited clinical signs or microscopic
evidence of vitamin deﬁciency. By the nature of the study designs,
most effects would have been detected. In addition, there was no
evidence that the vitamin levels detected in the EPG studies were
signiﬁcantly different from those reported in the published litera-
ture for normal control animals. In the long-term EPG studies, the
levels of fat-soluble vitamins increased and stabilized over time to
fall within normal ranges reported in the literature, despite being
signiﬁcantly lower statistically than those of the corresponding
control group animals.
As one of the articles in this series describes, in humans,
consumption of EPG in spread, mufﬁns, cookies, and biscuits at
10, 25, and 40 g/day (vs. margarine alone) for eight weeks was
not associated with any effects on circulating retinol, a-tocopherol,
or 25-OH D2 (vitamin D, ergocalciferol). However, circulating
b-carotene and phylloquinone (vitamin K1) were lower in the
EPG groups, and the levels of PIVKA-II (proteins induced in vitamin
K absence) were higher; 25-OH D3 (vitamin D, cholecalciferol)
increased but to a lesser extent than the control. An association
of these observations to EPG treatment could not be established
with any certainty, because b-carotene showed no apparent rela-
tionship to EPG concentration (more severe at 10 and 40 g/day
than at 25 g/day) and 25-OH D3 rose unexpectedly in the control
(margarine only) group. The decline in phylloquinone levels and
corresponding rise in PIVKA-II were small, and there was no
indication of any clinical manifestation. The changes in clotting
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comparable between the control and EPG groups, which is consis-
tent with the experimental animal study results.
In assessing the possible affect of EPG on lipid-soluble nutrients,
it is important to consider that EPG might act as a lipid ‘‘sink’’ or
additional ‘‘compartment’’ for the distribution of lipid-soluble sub-
stances, including fat-soluble vitamins present in the gut lumen.
EPG is not severely hydrophobic, exhibiting an octanol/water par-
tition coefﬁcient (Kow) value in the range of 3.2–3.4, similar to the
triglyceride fats it is intended to replace. Accordingly, lipid-soluble
substances partitioning into EPG are not strongly held and can
readily repartition back into the aqueous phase, establishing an
equilibrium state. While lipid-soluble nutrients are continuously
absorbed from the gut lumen by the usual physiological processes,
the solubility equilibrium would be expected to draw more of the
nutrient from the EPG compartment. As the unabsorbable EPG pro-
gresses down the gastrointestinal tract, beyond the area of active
nutrient absorption, it would still retain a certain amount of the
lipid-soluble nutrient. The amount retained would be in part
proportional to the mass of EPG present. This consideration may
in great part account for the observed, generally small effects on
fat-soluble nutrient levels in EPG studies, including those seen in
the 8-week human study. Importantly, projected consumer expo-
sure (90th percentile no greater than approximately 20 g EPG per
day) from the anticipated initial food uses would not be expected
to signiﬁcantly affect normal absorption of lipid-soluble nutrients.
4.2. Gastrointestinal effects
Olestra intake has reportedly been associated with gastrointes-
tinal symptoms, including loose stools. This effect is considered
similar to the effect of mineral oil, which interferes with the devel-
opment of ﬁrm, well-formed stools (61 FR, 3118; January 30,
1996). The potential of EPG to induce similar effects was assessed
through multiple studies.
Early in its development, it became evident that less viscous (i.e.,
liquid) versions of EPG resulted in passive oil leakage at lower die-
tary concentrations than semi-solid or solid versions. As such, the
research has focused on semi-solid and solid forms. Administration
of these forms of EPG to experimental animals and humans has not
resulted in any adverse effects on gastrointestinal physiology.
Occasional separation of the test material from stool bulk has
been observed at the highest levels of EPG exposure (up to 150 g/
day), but the incidence of loose stool and other gastrointestinal
symptoms declines with decreasing dietary concentrations. For
example, human volunteers receiving 25 or 40 g/day of a lower-
melting (99.3 F) semi-solid variant of the core EPG version in food
items (spread and baked goods) for eight weeks, reported gastroin-
testinal adverse events (gas, soft stool, oily spotting, etc.) more fre-
quently than subjects receiving margarine alone. However, at 10 g/
day, the only statistically signiﬁcant difference from the control
(margarine) group was oily spotting (see article in this series).
5. Conclusions
The structure of EPGs, being comprised of components of edible
fats and oils interrupted by simple propylene glycol units, providesa basis for a strong presumption of safety. This presumption has
been conﬁrmed by the results of an extensive array of nonclinical
investigations, including lifetime feeding studies and those examin-
ing reproduction and developmental endpoint at doses up to 5 g
EPG/kg body weight/day. No indication of toxicity was observed
in any study.
Low digestibility and caloric release was conﬁrmed, as was lack
of absorption of EPG following oral administration; EPG was not
found in any tissue after up to a lifetime of feeding in rats.
Clinical and nonclinical investigation of potential for nontoxic
effects attributable to the physical state, consumed mass and
solubility properties of EPG indicated low potential for signiﬁ-
cant or biologically meaningful effects at intake amounts antici-
pated for consumers. Gastrointestinal tolerance and tidiness
were found to be augmented through selection of versions that
are solid at human body temperature. Similarly, the potential
for these untoward effects was minimized through selection of
initial food applications that result in moderate consumer intake.
Finally, studies in both experimental animals and humans dem-
onstrated that: (1) the potential for interaction with lipid-soluble
nutrients and other substances present in the gastrointestinal
lumen is minimized through version selection (i.e., a solid form
of EPG) and moderation of consumption; and (2) there is low
potential for biologically-meaningful effects at the maximum
anticipated consumer intake. This is consistent with the moder-
ate organic nature and solubility properties of EPG (Kow of
approximately 3.2–3.4), and in strong contrast to the interaction
of fat mimetics, such as olestra which have a Kow in excess of
40.
Taken as a whole, the extensive chemistry and safety data base
provides a clear and strong basis to conclude that the consumption
of EPG in the anticipated uses would entail a reasonable certainty
that no harm would result.Conﬂict of interest statement
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